Helsinn Birex Patent-Cliff Exposure & CMS Drug Spending Portfolio

Helsinn Birex (US): 1 reconciled FDA prescription therapies (100.0% 2025 to 2030 cliff risk), $16.5M 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure100.0%
Primary Portfolio LOE Date2029-01-01
2024 CMS Total Public Spend$16.5M
2024 Medicare Part D Spend$13.9M
2024 Medicaid Spend$2.6M
California HCAI SB 17 Filings3 WAC filings (max 24.5% 2-yr change)